StockData
Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc. (RCKT) stock

RCKTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 3/30
$2.11+0.00 (0.00%)

Close on Nov 18, 2026Market cap $231.62MP/E –Yield –

Rocket Pharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

Rocket Pharmaceuticals's total assets was $423.10M at Jun 30, 2026. For fiscal 2025 it was $330.45M, down 37.4% from the year before. Over ten years it grew 11.3% a year on average. The highest annual figure on record is $590.82M in fiscal 2020.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$330.45M-37.4%
FY2024Dec 31, 2024$527.70M-6.8%
FY2023Dec 31, 2023$566.34M+2.6%
FY2022Dec 31, 2022$551.81M+11.0%
FY2021Dec 31, 2021$497.02M-15.9%
FY2020Dec 31, 2020$590.82M+58.8%
FY2019Dec 31, 2019$372.12M+48.1%
FY2018Dec 31, 2018$251.31M+1147.4%
FY2017Dec 31, 2017$20.15M-84.5%
FY2016Dec 31, 2016$129.65M+14.4%
FY2015Dec 31, 2015$113.32M+1952.9%
FY2014Dec 31, 2014$5.52M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$423.10M+0.5%
Q1 FY2026Mar 31, 2026$285.41M-39.4%
Q4 FY2025Dec 31, 2025$330.45M-37.4%
Q3 FY2025Sep 30, 2025$368.03M-6.5%
Q2 FY2025Jun 30, 2025$420.98M-5.7%
Q1 FY2025Mar 31, 2025$471.07M-5.7%
Q4 FY2024Dec 31, 2024$527.70M-6.8%
Q3 FY2024Sep 30, 2024$393.69M-34.2%
Q2 FY2024Jun 30, 2024$446.41M-3.3%
Q1 FY2024Mar 31, 2024$499.44M-3.0%
Q4 FY2023Dec 31, 2023$566.34M+2.6%
Q3 FY2023Sep 30, 2023$598.76M+43.5%
Q2 FY2023Jun 30, 2023$461.78M+6.9%
Q1 FY2023Mar 31, 2023$514.76M+11.9%
Q4 FY2022Dec 31, 2022$551.81M+11.0%
Q3 FY2022Sep 30, 2022$417.27M-21.3%
Q2 FY2022Jun 30, 2022$431.85M-19.3%
Q1 FY2022Mar 31, 2022$460.15M-20.2%
Q4 FY2021Dec 31, 2021$497.02M-15.9%
Q3 FY2021Sep 30, 2021$530.24M+58.0%
Q2 FY2021Jun 30, 2021$535.15M+51.6%
Q1 FY2021Mar 31, 2021$576.48M+54.7%
Q4 FY2020Dec 31, 2020$590.82M+58.8%
Q3 FY2020Sep 30, 2020$335.50M+11.9%
Q2 FY2020Jun 30, 2020$353.07M+14.4%
Q1 FY2020Mar 31, 2020$372.75M+53.9%
Q4 FY2019Dec 31, 2019$372.12M+48.1%
Q3 FY2019Sep 30, 2019$299.91M+53.8%
Q2 FY2019Jun 30, 2019$308.72M+48.7%
Q1 FY2019Mar 31, 2019$242.14M+11.5%
Q4 FY2018Dec 31, 2018$251.31M+1147.4%
Q3 FY2018Sep 30, 2018$194.98M+86.3%
Q2 FY2018Jun 30, 2018$207.57M+86.9%
Q1 FY2018Mar 31, 2018$217.17M+84.2%
Q4 FY2017Dec 31, 2017$20.15M-84.5%
Q3 FY2017Sep 30, 2017$104.66M-25.3%
Q2 FY2017Jun 30, 2017$111.07M–
Q1 FY2017Mar 31, 2017$117.92M–
Q4 FY2016Dec 31, 2016$129.65M–
Q3 FY2016Sep 30, 2016$140.14M–

More Rocket Pharmaceuticals figures

See a number that looks wrong?